S

Sage Therapeutics
D

SAGE

5.04000
USD
-0.23
(-4.27%)
مغلق
حجم التداول
61,108
الربح لكل سهم
-6
العائد الربحي
-
P/E
-1
حجم السوق
308,313,246
أصول ذات صلة
    C
    CLLS
    -0.03000
    (-1.78%)
    1.66000 USD
    C
    CRSP
    -3.490
    (-7.83%)
    41.110 USD
    E
    EDIT
    -0.17500
    (-11.51%)
    1.34500 USD
    F
    FOLD
    -0.31000
    (-3.14%)
    9.57000 USD
    Q
    QURE
    -0.750
    (-4.55%)
    15.740 USD
    R
    RCKT
    -0.160
    (-1.34%)
    11.750 USD
    S
    SGEN
    0
    (0%)
    0.000000 USD
    المزيد
الأخبار

العنوان: Sage Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.